You are here: Industry Insights > Bharat Biotech

News List

Monthly production capacity of Covishield projected to increase to 120 million doses, Covaxin to 58 million doses: Minister expresspharma
August 05, 2021
The monthly production capacity of Covishield is projected to be increased to more than 120 million doses, and of Covaxin to around 58 million doses by December, the government told Rajya Sabha August 3, citing information from the COVID-19 vaccine ...
Bharat Biotech’s ROTAVAC 5D receives WHO pre-qualification expresspharma
August 03, 2021
Bharat Biotech has announced that the World Health Organization (WHO) has awarded pre-qualification to its rotavirus vaccine, ROTAVAC 5D.
CDSCO grants permission to three private COVID-19 vaccines for restricted use in emergency situation expresspharma
July 21, 2021
The information was given today by Mansukh Mandaviya, Union Minister of Chemicals and Fertilizers, in a written reply in the Lok Sabha.
Centre to buy Covishield and Covaxin at revised rates expresspharma
July 20, 2021
The price of each dose of Covishield amounts to Rs 215.25, and Covaxin Rs 225.75, including taxes.
Ocugen seeks approval for Covaxin in Canada expresspharma
July 19, 2021
The move follows the release by Bharat Biotech of Phase 3 clinical trial results, which demonstrated efficacy and safety in nearly 25,800 adults, it said.
Ocugen commences rolling submission of COVAXIN to Health Canada pharmaceutical-technology
July 16, 2021
Ocugen has commenced the rolling submission to Health Canada for its Covid-19 vaccine candidate, COVAXIN, which is being jointly developed with Bharat Biotech International for use in the US and Canada.
Striving to increase vaccine availability through imports: Govt expresspharma
July 09, 2021
MEA Spokesperson Arindam Bagchi said India hopes that individual countries would increasingly recognise made-in-India vaccines.
Bharat Biotech announces data from phase-III Covaxin clinical trials expresspharma
July 05, 2021
Covaxin was well-tolerated and the Data Safety Monitoring Board has not reported any safety concerns related to the vaccine, the company said in a statement.
Posts on social media misrepresented facts, Covaxin end product doesn’t have newborn calf serum: Centre expresspharma
June 18, 2021
Newborn calf serum is used only for the preparation and growth of vero cells. Serum from bovine and other animal are standard enrichment ingredient used globally for vero cell growth, it said.
Jubilant HollisterStier partners with Ocugen to make Covaxin for US, Canadian markets expresspharma
June 17, 2021
Jubilant HollisterStier has manufacturing units in Spokane (US) and Montreal (Canada).

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page